~~<i id='2240D85D9C'><strike id='2240D85D9C'><tt id='2240D85D9C'><pre id='2240D85D9C'></pre></tt></strike></i>~~

Home» focus» leisure time

leisure time

author：comprehensive 2025-09-29 10:41:42 Page View：22

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： UpToDate has a racism problem: Dr. Stanley Goldfarb
Next article： Cancer drug shortages should be causing more outrage

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Illustration:ChristineKao/STAT;Photos:GettyTheunsettlingrealityofH5N1birdflucirculatingindairycowher

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

UpToDate has a racism problem: Dr. Stanley Goldfarb

AdobeTheUniversityofPennsylvania’sDivisionofRenal-ElectrolyteandHypertensionrecentlymadeaquietupdate